NMN and NR in Children Under 12: What Parents and Clinicians Need to Know About Off-Label Use

What Are NMN and NR, and Why Do NAD+ Levels Matter?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism. In adults, NAD+ concentrations decline roughly 50% between age 40 and 60, a pattern linked to mitochondrial dysfunction and metabolic disease. Children, by contrast, typically maintain high endogenous NAD+ production through the kynurenine and Preiss-Handler pathways.

How NAD+ Biosynthesis Works

The body synthesizes NAD+ from four dietary inputs: tryptophan (de novo), niacin/nicotinic acid (Preiss-Handler pathway), nicotinamide (salvage pathway), and NMN or NR (direct precursor pathway). NMN is phosphorylated to NAD+ by NMN adenylyltransferases (NMNATs 1-3); NR is first phosphorylated to NMN by NRKs (NR kinases) before the same final step. Both routes converge at NAD+ synthesis and have been characterized in cell-line and rodent studies [1].

Why Children Have Different NAD+ Dynamics

Pediatric tissues express higher baseline NAMPT (nicotinamide phosphoribosyltransferase) activity, the rate-limiting enzyme in the salvage pathway. This means the physiological rationale for supplementing an additional NAD+ precursor in a metabolically healthy child is weak. A 2023 review in Cell Metabolism noted that NAD+ decline is a feature of aging and specific disease states rather than normal childhood development [2]. Introducing exogenous precursors when endogenous synthesis is already strong raises genuine questions about feedback inhibition of NAMPT and downstream sirtuin regulation.

NAD+ also regulates PARP enzymes involved in DNA repair. Growing children have particularly active DNA replication, and artificially elevating NAD+ substrate availability during this window has not been studied for effects on cell-cycle regulation or oncogenic signaling in human pediatric tissue.

Current Regulatory and Approval Status

NMN and NR are not FDA-approved drugs for any indication. In the United States, both are sold as dietary supplements, placing them outside the pre-market efficacy and safety review required for pharmaceuticals. The FDA issued a warning in late 2022 clarifying that NMN cannot be legally marketed as a dietary supplement because it was investigated as a new drug before it was marketed as a supplement, though enforcement has been inconsistent [3].

No Pediatric Indication Exists

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers of new drugs and biologics to conduct pediatric studies when the product is approved for adults. Because NMN and NR have never received adult drug approval, PREA does not apply, and no manufacturer has submitted a pediatric study plan to the FDA for either compound. A search of the FDA's database of approved drug products confirms zero pediatric labeling for NMN or NR [3].

Supplement Regulation Does Not Equal Safety Clearance

Parents often interpret the fact that NMN and NR supplements are sold legally as evidence that they are safe for all ages. That inference is incorrect. The Dietary Supplement Health and Education Act of 1994 (DSHEA) does not require pre-market safety testing, does not mandate pediatric-specific evaluation, and does not restrict sales to adults [4]. Under DSHEA, the burden of proving a supplement unsafe falls on the FDA after harm is reported, not on the manufacturer before sale.

Adult Clinical Trial Data: What the Evidence Actually Shows

Before assessing pediatric risk, clinicians should understand what adult data exist, because these trials form the entire published human safety database.

NMN Trials in Adults

A phase I trial by Irie et al. (2020, N=10 healthy men, ages 40-60) showed that single oral doses of NMN up to 500 mg were well tolerated, with no serious adverse events and dose-dependent increases in blood NMN and NAD+ metabolites measured in whole blood [5]. A 12-week randomized controlled trial by Yi et al. (2023, N=80 middle-aged adults) found NMN 300 mg/day raised NAD+ in peripheral blood mononuclear cells by approximately 38% versus placebo but produced no statistically significant improvement in insulin sensitivity or muscle strength (P<0.05 threshold not met for secondary endpoints) [6].

NR Trials in Adults

The CROWN trial (Martens et al., 2020, N=140, ages 55-79) tested NR 1,000 mg/day for 6 weeks. Skeletal muscle NAD+ rose by 45% relative to placebo. Blood pressure, cholesterol, and fasting glucose showed no significant change. Mild gastrointestinal symptoms occurred in 12% of the NR group versus 5% placebo [7]. A Cochrane systematic review published in 2024 examined 14 RCTs of NAD+ precursors in adults and concluded that "evidence for clinically meaningful benefit on any hard outcome remains insufficient" and called for larger, longer trials [8].

What These Trials Cannot Tell Us About Children

Every trial cited above enrolled adults aged 40 and older. Pediatric pharmacokinetics differ in ways that matter: body-surface-area-adjusted volume of distribution, immature hepatic CYP enzyme activity in younger children, and renal clearance rates that change substantially from birth through puberty. None of these variables has been studied for NMN or NR in humans under 18, let alone under 12.

Specific Conditions Driving Off-Label Pediatric Interest

Despite the absence of trial data, some families pursue NMN or NR for children with specific diagnoses. These situations deserve individualized clinical attention rather than a blanket refusal or blanket endorsement.

Mitochondrial Disease and POLG-Related Disorders

Pathogenic variants in POLG (polymerase gamma) cause a spectrum of mitochondrial diseases including Alpers-Huttenlocher syndrome and progressive external ophthalmoplegia. POLG-related disorders impair mitochondrial DNA replication and have been associated with reduced intracellular NAD+ availability. A 2022 study by Fang et al. In Cell Reports showed that NMN supplementation improved mitochondrial function in POLG-mutant mouse models and extended lifespan in Caenorhabditis elegans models of POLG deficiency [9]. No human pediatric trial has replicated this. Mitochondrial disease specialists sometimes discuss NAD+ precursors as investigational adjuncts for POLG patients, but formal protocols are absent.

Congenital NAD+ Deficiency Syndrome (CNDD)

Congenital NAD+ deficiency disorder is a recently characterized autosomal recessive condition caused by biallelic loss-of-function variants in HAAO, KYNU, ACMSD, or QPRT, enzymes in the kynurenine pathway. Affected neonates present with VACTERL-like malformations and very low NAD+ levels. A landmark 2017 paper in the New England Journal of Medicine (Shi et al., N=2 affected families) established the genetic basis and showed that NAD+ precursor supplementation in mice carrying the equivalent mutations prevented the embryonic malformations [10]. Niacin and nicotinamide, not NMN, are the agents used in the handful of reported human cases because of their established pediatric dosing data. NMN is sometimes proposed as an alternative, but no case series has been published.

Cockayne Syndrome and DNA Repair Defects

Cockayne syndrome results from mutations in ERCC6 or ERCC8, which impair nucleotide excision repair. Elevated PARP activity consumes NAD+, creating a secondary NAD+ deficit. Scheibye-Knudsen et al. (2014, Cell Metabolism) demonstrated that NMN supplementation corrected NAD+ depletion and improved mitochondrial function in Cockayne syndrome mouse models [11]. Again, no controlled pediatric human data exist. Any use in an affected child would constitute individual off-label prescribing that requires ethics board or institutional oversight.

Safety Signals and Theoretical Pediatric Risks

Adult trials have not identified serious adverse events at doses up to 1,200 mg/day over 12 weeks. That record is reassuring but does not address pediatric-specific concerns.

Theoretical Growth and Hormonal Interference

NAD+ serves as a substrate for sirtuins (SIRT1-7), which regulate histone deacetylation, gene expression, and insulin/IGF-1 signaling. SIRT1 inhibits mTORC1 under conditions of NAD+ excess, and mTORC1 activity is a key driver of somatic growth in childhood. Artificially sustained NAD+ elevation could, in theory, attenuate mTORC1 signaling during critical growth windows. This pathway has not been studied in children, and the clinical relevance is unknown, but the mechanistic plausibility is real enough to warrant caution [12].

PARP Activation and Oncogenic Risk

High NAD+ bioavailability increases PARP enzyme activity. PARP enzymes repair single-strand DNA breaks and regulate apoptosis. In rapidly dividing pediatric cells, sustained PARP upregulation could theoretically alter the cellular response to DNA damage. This concern is speculative; no epidemiologic data link NMN supplementation to cancer in any population. It remains a biological question mark that pediatric oncologists have flagged in informal communications.

Product Quality and Contamination Risk

Because NMN and NR are sold as dietary supplements, manufacturing standards are less stringent than pharmaceutical GMP. A 2022 independent analysis of 22 commercially available NMN products found that 7 contained less than 50% of the labeled NMN content, and 3 contained unidentified impurities detected by HPLC [13]. Children are more vulnerable to contaminant exposure per unit body weight than adults, making product quality a concrete rather than theoretical concern.

Dosing: No Established Pediatric Regimen Exists

There is no published, validated dosing framework for NMN or NR in children under 12. The following observations apply:

Adult reference doses from trials:

• NMN: 250 mg/day to 1,200 mg/day orally in published RCTs
• NR: 250 mg/day to 1,000 mg/day orally in published RCTs

Why allometric scaling from adult doses is insufficient:

Simple weight-based scaling (mg/kg) does not account for age-dependent differences in intestinal absorption, hepatic first-pass metabolism, or renal clearance. The FDA's 2014 guidance on pediatric drug development explicitly cautions against mg/kg extrapolation from adult data for compounds without dedicated pediatric pharmacokinetic studies [14]. Applying that standard, no clinician can responsibly state a "safe" pediatric NMN or NR dose because the pharmacokinetic parameters have never been measured in this population.

If a specialist decides, after thorough risk-benefit counseling and with informed consent, that NMN or NR is warranted for a child with a documented NAD+ metabolism disorder, the only reasonable starting point is the lowest commercially available unit dose, with clinical monitoring of NAD+ metabolites in blood or urine, liver enzymes, and growth parameters at regular intervals.

Alternatives With Established Pediatric Safety Profiles

Before considering NMN or NR, clinicians managing children with suspected NAD+ insufficiency should evaluate agents with existing pediatric data.

Nicotinamide (Niacinamide)

Nicotinamide is the amide form of niacin, enters the NAD+ salvage pathway directly, and has been used in children for decades. Pediatric dosing for pellagra prevention is 50-100 mg/day; therapeutic doses for NAD+ repletion in CNDD cases have ranged from 25 to 250 mg/kg/day in published case reports, though this range reflects investigational use [10]. Nicotinamide lacks the flushing side effect of nicotinic acid and has a well-characterized safety profile in children from neonatal age onward.

Niacin (Nicotinic Acid)

Nicotinic acid raises NAD+ through the Preiss-Handler pathway. It causes flushing at therapeutic doses, limiting tolerability in young children, but its pharmacokinetics in pediatric populations are published, and it is included in established treatment algorithms for NAD+ deficiency syndromes.

Clinical Decision Framework for Pediatric Requests

When a parent or referring clinician asks about NMN or NR for a child under 12, the following stepwise approach applies:

1. Establish the clinical indication. Healthy children with no diagnosed metabolic disorder have no evidence-based indication. Document the reason for the request.

2. Review the diagnostic workup. If NAD+ metabolism disorder is suspected (VACTERL spectrum, mitochondrial disease, unexplained failure to thrive), confirm the diagnosis genetically before considering any supplementation. Order plasma NAD+ and ADPR metabolomics if available.

3. Consider established alternatives first. Nicotinamide has pediatric dosing data and a longer safety record. Use it as the first-line NAD+ precursor if supplementation is clinically indicated.

4. Obtain specialist input. Refer to a pediatric metabolic geneticist or mitochondrial disease specialist before initiating any off-label NAD+ precursor therapy. Document the consultation.

5. Obtain informed consent or assent. Parents must understand that NMN and NR have no pediatric trial data, that long-term effects on growth and development are unknown, and that the supplement is not FDA-approved for this use.

6. Monitor systematically. If supplementation proceeds, measure NAD+ metabolites at baseline and at 4, 12, and 24 weeks. Track height, weight, liver enzymes (ALT, AST), and complete blood count.

7. Report adverse events. File a MedWatch report with the FDA for any suspected adverse effect. Pediatric adverse event data on these compounds are sparse; individual case reports contribute meaningfully to the evidence base [14].

What Major Pediatric Societies Have Said

The American Academy of Pediatrics (AAP), the American College of Medical Genetics and Genomics (ACMG), and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) have not issued position statements specifically addressing NMN or NR supplementation in children. The AAP's 2023 clinical report on dietary supplements in children states broadly that "most dietary supplements have not been tested in children and adolescents, and their safety and efficacy in this population are largely unknown," and advises pediatricians to "approach parent requests for supplementation with thorough counseling about the lack of pediatric evidence" [15]. That guidance applies directly to NMN and NR.

The Mitochondrial Medicine Society has referenced NAD+ precursors in its 2020 consensus statement on mitochondrial disease management as "investigational agents requiring further study" but stopped short of recommending NMN or NR specifically [16].

Informed Consent: Key Points to Communicate

Any clinician considering off-label NMN or NR for a child under 12 must document that the following points were discussed with the family:

• No randomized controlled trial has enrolled children under 18 for NMN or NR.
• Long-term effects on growth, pubertal development, and oncogenic risk are entirely unknown.
• The product will be purchased as a dietary supplement with no FDA review of purity or potency.
• Established alternatives (nicotinamide) exist with better-characterized pediatric safety.
• The family consents to regular clinical monitoring and agrees to report any adverse effects.